BCDA Rega marang bathi mangsa ngarep BioCardia

BioCardia Inc - logo grafis emiten BCDA

The cardiology sector is currently constrained by lengthy FDA approval processes, leaving BioCardia, Inc. (BCDA) reliant on grants for survival. Revenues are based on cardiac cell therapy via CardiAMP systems, while sales of Helix catheters for ischemia provide a cash inflow from surgical centers. The company's forward P/E ratio demonstrates valuation dynamics, where the value 0.00 reflects the metric's balance at the current stage.

BCDA - Prakiraan rega marang bathi biocardia.com ing rentang 04.07.2022 - 10.11.2026

Rincian metrik keuangan lan pasar BioCardia Inc (BCDA)

- kuotasi lan prakiraan analis:
Rega saham BioCardia|BCDA - Target median analis
- data kapitalisasi pasar:
Nilai pasar BioCardia Inc.|BCDA - Total Nilai Perusahaan
- data ekuitas miturut neraca:
Nilai Buku saben Saham BioCardia|BCDA - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku biocardia.com|BCDA - Total Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas BioCardia, Inc.|BCDA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal BioCardia, Inc.|BCDA - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku BioCardia Inc.|BCDA - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan BioCardia|Indikator likuiditas cepet biocardia.com
- statistik bathi lan rasio pasar:
BCDA - Bathi pungkasan|Proyeksi bathi mangsa ngarep BioCardia, Inc.|BCDA - Periode bali modal bisnis|Rega marang bathi mangsa ngarep BioCardia, Inc|BCDA - Rasio P/E diaturake wutah|Pangali EV/EBITDA BioCardia Inc.|BCDA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan BioCardia|BCDA - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan biocardia.com|BCDA - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BioCardia, Inc.
Ringkesan analitik perusahaan:BioCardia
Produk mawa merek BioCardia Inc

Driven by the unique CardiAMP system and inelastic patient demand, BioCardia, Inc. (BCDA) possesses exceptional pricing power within the myocardial therapy market. By analyzing the company's forward P/E ratio history, an investor assesses the relationship between current quotes and projected earnings, where low values may indicate either an undervalued asset or market skepticism regarding the business's ability to monetize its developments.

Pesaing utama

Pangali Forward P/E REGN|Kapitalisasi marang proyeksi bathi iRhythm Technologies, Inc.|Rega marang bathi mangsa ngarep Lantheus Medical Imaging LNTH|Mineralys Corp (MLYS) - Rasio prakiraan rega marang bathi|HeartFlow, Inc. - Pangali Forward P/E|kestramedical.com (KMTS) - Prakiraan rega marang bathi|ESPR: Pangali Forward P/E|Amarin Corporation (AMRN) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Anteris|TNYA: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E CVRX|milestonepharma.com - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E CRDL (Cardiol Therapeutics Inc.)|Kapitalisasi marang proyeksi bathi HeartBeam Inc (BEAT)|Tenax Therapeutics, Inc - Pangali Forward P/E|ADGM - Pangali Forward P/E|VTAK (Catheter Precision) - Prakiraan rega marang bathi|ARCA Biopharma, Inc. - Pangali mangsa ngarep rega marang bathi|ACST (Acasti Pharma Inc) - Pangali Forward P/E|Aerovate Therapeutics Inc. (AVTE) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Verve Therapeutics (VERV)|windtreetx.com - Rasio rega marang bathi mangsa ngarep